CLASS ACTION UPDATE for BLU, ATNX and XL: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

·4 min read

NEW YORK, NY / ACCESSWIRE / April 19, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

BLU Shareholders Click Here: https://www.zlk.com/pslra-1/bellus-health-inc-loss-submission-form?prid=14840&wire=1
ATNX Shareholders Click Here: https://www.zlk.com/pslra-1/athenex-inc-loss-submission-form?prid=14840&wire=1
XL Shareholders Click Here: https://www.zlk.com/pslra-1/xl-fleet-corp-loss-submission-form?prid=14840&wire=1

* ADDITIONAL INFORMATION BELOW *

BELLUS Health Inc. (NASDAQ:BLU)

BLU Lawsuit on behalf of: investors who purchased September 5, 2019 - July 5, 2020
Lead Plaintiff Deadline: May 17, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/bellus-health-inc-loss-submission-form?prid=14840&wire=1

According to the filed complaint, during the class period, BELLUS Health Inc. made materially false and/or misleading statements and/or failed to disclose that: while BLU-5937's "high selectivity" contributed to the drug causing little to no taste alteration in chronic cough patients, that high selectivity also contributed to the drug potentially being less efficacious and thus likely not be able to meet the primary endpoint of the Company's Phase 2 trial.

Athenex, Inc. (NASDAQ:ATNX)

ATNX Lawsuit on behalf of: investors who purchased August 7, 2019 - February 26, 2021
Lead Plaintiff Deadline: May 3, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/athenex-inc-loss-submission-form?prid=14840&wire=1

According to the filed complaint, during the class period, Athenex, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the data included in the Oral Paclitaxel plus Encequidar NDA presented a safety risk to patients in terms of an increase in neutropenia-related sequalae; (ii) the uncertainty over the results of the primary endpoint of objective response rate (ORR) at week 19 conducted by BICR; (iii) the BICR reconciliation and re-read process may have introduced unmeasured bias and influence on the BICR; (iv) the Company's Phase 3 study that was used to file the NDA was inadequate and not well-conducted in a patient population with metastatic breast cancer representative of the U.S. population, such that the FDA would recommended a new such clinical trial; (v) as a result, it was foreseeable that the FDA would not approve the Company's NDA in its current form; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

XL Fleet Corp. (NYSE:XL)

XL Lawsuit on behalf of: investors who purchased October 2, 2020 - March 2, 2021
Lead Plaintiff Deadline: May 7, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/xl-fleet-corp-loss-submission-form?prid=14840&wire=1

According to the filed complaint, during the class period, XL Fleet Corp. made materially false and/or misleading statements and/or failed to disclose that: (1) XL Fleet's salespeople were pressured to inflate their sales pipelines to boost the Company's reported sales and backlog; (2) at least 18 of the 33 customers that XL featured were inactive and had not placed an order since 2019; (3) XL's technology had been materially overstated and offered only 5% to 10% of fleet savings; (4) XL lacks the supply chain and engineers to roll out new products on the announced timelines; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP



View source version on accesswire.com:
https://www.accesswire.com/641101/CLASS-ACTION-UPDATE-for-BLU-ATNX-and-XL-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders